ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies
americanpharmaceuticalreview
September 03, 2018Pfizer announced it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004).
Pharma Sources Insight July 2025
